Applicant: Yang et al. 'Serial No: 09/645,967

JAN 0 2 2002 G

Am ndments

Please amend claims 1 and 20 as follows:

3

(amended).

A compound of the formula:

RECEIVED

JAN 0 9 2002 TECH CENTER 1600/2900

wherein

n is 1 or 2;

 ${\bf R^{28}}$ and ${\bf R^{43}}$ are independently selected from the group consisting of H and a substituted or unsubstituted aliphatic or acyl moiety;

one of $\mathbf{R^{7a}}$ and $\mathbf{R^{7b}}$ is H and the other is halo, $-\mathbf{R^A}$, $-\mathrm{OR^A}$, $-\mathrm{SR^A}$, $-\mathrm{OC(O)R^A}$, $-\mathrm{OC(O)NR^AR^B}$, $-\mathrm{NR^BC(O)R^A}$, $-\mathrm{NR^BC(O)OR^A}$, $-\mathrm{NR^BSO_2R^A}$ or $-\mathrm{NR^BSO_2NR^AR^B}$; or $\mathbf{R^{7a}}$ and $\mathbf{R^{7b}}$, taken together, are H in the tetraene moiety:

where $\mathbf{R}^{\mathbf{A}}$ is H or a substituted or unsubstituted aliphatic, heteroaliphatic, aryl, or heteroaryl moiety and where $\mathbf{R}^{\mathbf{B}}$ is H, OH or a substituted or unsubstituted aliphatic, heteroaliphatic, aryl, or heteroaryl moiety; $\underline{\mathbf{r}}$ $\underline{\mathbf{a}}$

[as a substantially pure stereoisomer or mixture of stereoisomers, and as an] pharmaceutically acceptable derivative thereof.

Applicant: Yang et al. ' Serial No: 09/645,967

Page 3

20 (amended). A compound of the formula:

wherein

n is 1 or 2;

 ${\bf R^{28}}$ and ${\bf R^{43}}$ are independently selected from the group consisting of H and a substituted or unsubstituted aliphatic or acyl moiety;

one of $\mathbf{R^{7a}}$ and $\mathbf{R^{7b}}$ is H and the other is halo, $-\mathbf{R^A}$, $-\mathrm{OR^A}$, $-\mathrm{SR^A}$, $-\mathrm{OC(O)R^A}$, $-\mathrm{OC(O)NR^AR^B}$, $-\mathrm{NR^BC(O)R^A}$, $-\mathrm{NR^BC(O)OR^A}$, $-\mathrm{NR^BSO_2R^A}$ or $-\mathrm{NR^BSO_2NR^AR^B}$; or $\mathbf{R^{7a}}$ and $\mathbf{R^{7b}}$, taken together, are H in the tetraene moiety:

where $\mathbf{R}^{\mathbf{A}}$ is H or a substituted or unsubstituted aliphatic, heteroaliphatic, aryl, or heteroaryl moiety and where $\mathbf{R}^{\mathbf{B}}$ is H, OH or a substituted or unsubstituted aliphatic, heteroaliphatic, aryl, or heteroaryl moiety; or a

[as a substantially pure stereoisomer or mixture of stereoisomers, and as an] pharmaceutically acceptable derivative thereof.

Attached hereto is a clean copy of the claims as modified by the foregoing amendments. The attached pages are entitled "Clean Copy of Amended Claims 1 and 20."